The availability of new drugs for patients with early Alzheimer’s symptoms has spurred them into action now, they say. The plan could be approved by the panel and published in a medical journal early this year, association officials said. “Should you diagnose Alzheimer’s disease in asymptomatic persons? The Alzheimer’s Association has been among the most vocal advocates for the two drugs, which each cost more than $26,000 a year. In its 2023 fiscal year, the Alzheimer’s Association received $4.9 million from pharmaceutical, biotech, diagnostic and clinical research companies — more than in any of the previous five years.

Source: Los Angeles Times February 20, 2024 19:24 UTC